(0.20%) 5 110.06 points
(0.28%) 38 348 points
(0.09%) 15 942 points
(-0.33%) $83.57
(2.39%) $1.969
(-0.26%) $2 341.20
(-0.25%) $27.47
(2.72%) $947.15
(0.02%) $0.935
(-0.07%) $11.02
(-0.21%) $0.799
(1.90%) $93.62
@ $15.77
发出时间: 15 Feb 2024 @ 03:20
回报率: -7.10%
上一信号: Feb 14 - 04:31
上一信号:
回报率: 6.45 %
Live Chart Being Loaded With Signals
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States...
Stats | |
---|---|
今日成交量 | 8 962.00 |
平均成交量 | 389 040 |
市值 | 641.33M |
EPS | $0 ( 2024-02-29 ) |
下一个收益日期 | ( $-0.120 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -29.90 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-12 | Tagliaferri Mary | Buy | 27 900 | Stock Option (right to buy) |
2024-03-12 | Tagliaferri Mary | Buy | 4 660 | Common Stock |
2024-02-29 | Tagliaferri Mary | Buy | 0 | |
2024-03-05 | Rajah Vignesh | Sell | 1 711 | Common Stock |
2024-03-05 | Gad Thomas | Sell | 3 900 | Common Stock |
INSIDER POWER |
---|
77.63 |
Last 98 transactions |
Buy: 3 651 211 | Sell: 357 293 |
Y-mAbs Therapeutics, Inc 相关性
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Y-mAbs Therapeutics, Inc 财务报表
Annual | 2023 |
营收: | $84.82M |
毛利润: | $73.40M (86.54 %) |
EPS: | $-0.490 |
FY | 2023 |
营收: | $84.82M |
毛利润: | $73.40M (86.54 %) |
EPS: | $-0.490 |
FY | 2022 |
营收: | $65.27M |
毛利润: | $57.70M (88.41 %) |
EPS: | $-2.20 |
FY | 2021 |
营收: | $34.90M |
毛利润: | $32.38M (92.80 %) |
EPS: | $-1.378 |
Financial Reports:
No articles found.
Y-mAbs Therapeutics, Inc
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。